Blood Spot Self-administered Test and Assay
Studie Overzicht
Toestand
Gedetailleerde beschrijving
Recent advances in cancer diagnosis and treatment have led to greater survival rates in patients with malignancies. However, these life-saving treatments, especially alkylating agents, often lead to premature ovarian failure, infertility and related long-term health problems. It is difficult to predict whether, and the extent to which, patients will experience these problems. There are no early clinical signs of decreased fertility potential; even young women who maintain cyclic menses after therapy are at high risk of infertility, early menopause and related health problems. Preliminary studies suggest that several surrogate measures of fertility potential are different in cancer survivors compared with controls. These include follicle stimulating hormone (FSH), estradiol, anti-mullerian hormone (AMH) and inhibin B. Large longitudinal studies are needed to validate these measures with gold standard outcomes such as pregnancy rates, pregnancy outcomes and time to menopause. The main impediment to assessing the value of these markers and generating data that is useful to cancer survivors is the need for frequent and timed blood samples.
Daily or frequent trips to the clinical center are not practical and reduce the compliance of even the most motivated patients. The hypothesis that will be tested by this study is that blood spot assays can be developed that provide robust, personalized data for surrogate markers of reproductive function which can be used to assess reproductive potential in women; furthermore, bloodspots collected at home are an acceptable method for reproductive hormone measurement in women with and without a history of cancer. The current study will compare hormone levels of AMH, FSH and inhibin B in blood specimens collected by venipuncture and fingerstick in a sample of subjects.
Studietype
Inschrijving (Werkelijk)
Contacten en locaties
Studie Locaties
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19143
- University of Pennsylvania, Reproductive Research Unit
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
The target population is 80 pre-menopausal women ages 18-45 years with normal menstrual cycles:
Aim 1: Total 80 subjects:
- 30 cancer survivors
- 30 similar aged healthy controls
- 20 late reproductive aged women
Aim 2: Subset of 60 subjects:
- 30 cancer survivors
- 30 similar aged healthy controls
Beschrijving
Inclusion Criteria:
- Adult females
- Age between 18-45 years
- Premenopausal (defined as menses in the past 12 months)
- Postmenarchal
- Presence of an intact uterus and two ovaries
- Ability and willingness to comply with study protocol
Exclusion Criteria:
- Pregnancy within the previous 3 months
- Lactation within the previous 3 months
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
|---|
|
Cancer Survivor
Pre-menopausal women who are cancer survivors ages 18-45 years with normal menstrual cycles.
|
|
Similar aged healthy controls
Pre-menopausal, healthy women ages 18-45 years with normal menstrual cycles
|
|
Late Reproductive Age
Pre-menopausal, healthy women of late reproductive age
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
AMH pg/mL in dried bloodspot vs serum samples
Tijdsspanne: Day 1
|
Serum AMH ELISA assay results will be compared to capillary blood sample AMH collected on filter paper and dried.
Recovery of spiked ligands, sensitivity and specificity of the assays will be also assessed.
|
Day 1
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Adequacy of subject's self-collected bloodspot sample vs. sample collected in clinic
Tijdsspanne: Day 1
|
A capillary blood sample from a finger-prick is applied to Whatman #903 filter paper, allowed to dry at room temperature for at least 4 hours, and then stored until analysis in the laboratory.
Subjects willing to conduct a finger stick at home will collect an additional dried blood spot sample for secondary outcome measures.
At home blood spot cards will be compared to those obtained in the office to determine adequacy of collection.
|
Day 1
|
|
Measures of user acceptability through subject report/feedback
Tijdsspanne: Day 1
|
Ease of use data reported by subject survey will be summarized to determine the overall acceptability of bloodspot collection and the potential for at- home use
|
Day 1
|
|
AMH pg/mL in cancer survivors vs. healthy control cohorts
Tijdsspanne: Day 1
|
AMH in dried blood spots vs. serum collected during the early follicular phase in 30 cancer survivors (15 exposed to low dose cancer therapy, 15 exposed to high dose cancer therapy) and 30 healthy similar aged controls will be compared using tests and multivariable linear regression
|
Day 1
|
|
FSH (mIU/mL) in dried bloodspot vs serum samples
Tijdsspanne: Day 1
|
Serum FSH ELISA assay results will be compared to FSH in a dried capillary blood sample applied to filter paper.
Recovery of spiked ligands and sensitivity and specificity of the assays will be assessed.
|
Day 1
|
|
Inhibin B (pg/ml) in dried bloodspot vs serum samples
Tijdsspanne: Day 1
|
Serum Inhibin B ELISA assay results will be compared to capillary blood sample Inhibin B collected on filter paper and dried.
Recovery of spiked ligands and sensitivity and specificity of the assays will be assessed.
|
Day 1
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Clarisa Gracia, MD, MSCE, University of Pennsylvania
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 812735
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Effecten van chemotherapie
-
University Hospital, GrenobleVoltooidAdrenerge bèta-2-agonist-effect | Albuterol-effectFrankrijk
-
University of ReadingComvita UKVoltooidAbsorptie en metabolisme | Effect op vasculaire functie | Effect op cytokineconcentratiesVerenigd Koninkrijk
-
Algemeen Ziekenhuis Maria MiddelaresNog niet aan het werven
-
Maimonides Medical CenterWerving
-
Namik Kemal UniversityVoltooid
-
University of Maryland, BaltimoreFood and Drug Administration (FDA)VoltooidWarmte-effectVerenigde Staten
-
General Hospital of Ningxia Medical UniversityVoltooid
-
North Dakota State UniversityVoltooidCryotherapie-effectVerenigde Staten
-
Institut Pasteur de LilleInstitut Polytechnique LaSalle BeauvaisVoltooid
-
University of CopenhagenGentofte Hospital, DenmarkWervingIncretine-effectDenemarken